Blood Platelet Disorders: Clinical Trials

472 trials for Blood Platelet Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

204 completed, 75 unknown, 67 recruiting, 61 terminated. 472 Phase 2, 77 Phase 1, 35 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2472Completed 204, Unknown 75, Recruiting 67, Terminated 61, Withdrawn 25, Not yet recruiting 22, Active not recruiting 18
Phase 177Completed 36, Recruiting 14, Terminated 11, Unknown 6, Withdrawn 4, Active not recruiting 3, Not yet recruiting 3
Phase 335Unknown 11, Completed 10, Terminated 5, Not yet recruiting 3, Recruiting 3, Active not recruiting 2, Withdrawn 1

Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders

Trials (filtered) newest first · largest first

All 472 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome
Phase 2Not yet recruitingNovelMed Therapeutics122027-11-012026-04-13
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruitingNovartis Pharmaceuticals362027-02-082026-06-25
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center352027-01-302026-11-05
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia
Hetrombopag and recombinant human thrombopoietin, Recombinant Human Thrombopoietin - Thrombocytopenia
Phase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University962026-12-012026-11-12
Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia
Phase 2Not yet recruitingPeking University People's Hospital902026-12-012026-11-12
Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia
Luspatercept, Pacritinib - Myelofibrosis
Phase 2Not yet recruitingCase Comprehensive Cancer Center502026-12-012026-11-13
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
Avatrombopag - Thrombocytopenia
Phase 2Not yet recruitingUniversity of Virginia262026-11-012026-10-26
Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation
Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2Not yet recruitingThe First Affiliated Hospital of Henan University of Science and Technology872026-11-012026-09-21
TGD001 Treatment in Thrombotic Microangiopathies
TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Phase 1 / Phase 2RecruitingTargED Biopharmaceuticals B.V.702026-10-252026-11-12
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 2RecruitingJohn Mascarenhas262026-10-232026-10-27
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Phase 2RecruitingNovartis Pharmaceuticals1642026-08-042026-11-06
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
ALN-6400 - Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Phase 2RecruitingAlnylam Pharmaceuticals242026-07-302026-11-13
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia
Phase 1 / Phase 2RecruitingCRISPR Therapeutics AG602026-07-172026-10-20
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles - Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
Phase 2RecruitingFudan University1262026-07-162026-11-02
Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.
Nplate, NaCl %0.9 - Chirurgical Intervention, Thrombocytopaenia
Phase 2RecruitingNantes University Hospital1422026-07-162026-10-28
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Eltrombopag - Immune Thrombocytopenia
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China402026-07-102026-07-07
TPO-RA Plus Baricitinib vs. TPO-RA for ITP
Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia
Phase 2Not yet recruitingPeking University People's Hospital1002026-07-012026-06-25
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Phase 2WithdrawnNovartis Pharmaceuticals2026-06-262026-10-15

Showing 20 of 472. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (168)  ·  Thrombocytopenia (158)  ·  Thrombocythemia, Essential (88)  ·  Polycythemia Vera (79)  ·  Primary Myelofibrosis (78)  ·  Myeloproliferative Disorders (64)  ·  Myelodysplastic Syndromes (44)  ·  Leukemia, Myeloid, Acute (40)  ·  Leukemia (39)  ·  Leukemia, Myelomonocytic, Chronic (35)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (33)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (30)  ·  Multiple Myeloma (29)  ·  Lymphoma, Non-Hodgkin (25)  ·  Leukemia, Myeloid, Accelerated Phase (23)

Broader conditions

Hemic and Lymphatic Diseases (472)  ·  Hematologic Diseases (457)  ·  Cytopenia (348)  ·  Blood Coagulation Disorders (293)  ·  Hemorrhagic Disorders (285)  ·  Pathologic Processes (271)  ·  Pathological Conditions, Signs and Symptoms (271)  ·  Immune System Diseases (238)  ·  Thrombotic Microangiopathies (196)  ·  Thrombocytopenia (194)  ·  Hemorrhage (188)  ·  Signs and Symptoms (188)  ·  Skin Manifestations (186)  ·  Purpura (183)

Interventions

eltrombopag (52)  ·  romiplostim (29)  ·  Dexamethasone (27)  ·  Cyclophosphamide (24)  ·  Rituximab (23)  ·  fludarabine phosphate (22)  ·  Peripheral Blood Stem Cell Transplantation (19)  ·  Busulfan (17)  ·  avatrombopag (17)  ·  Cyclosporine (16)  ·  Tacrolimus (14)  ·  ruxolitinib (13)  ·  Danazol (12)  ·  Whole-Body Irradiation (12)  ·  Methotrexate (11)

Sponsors

Peking University People's Hospital (43)  ·  Institute of Hematology & Blood Diseases Hospital, China (27)  ·  M.D. Anderson Cancer Center (14)  ·  National Heart, Lung, and Blood Institute (NHLBI) (14)  ·  Shandong University (14)  ·  Fred Hutchinson Cancer Center (12)  ·  Novartis Pharmaceuticals (11)  ·  Amgen (10)  ·  GlaxoSmithKline (8)  ·  Alexion Pharmaceuticals, Inc. (7)  ·  Weill Medical College of Cornell University (7)  ·  National Cancer Institute (NCI) (6)  ·  Mayo Clinic (5)  ·  Memorial Sloan Kettering Cancer Center (5)  ·  Peking Union Medical College Hospital (5)

Countries

United States (213)  ·  China (121)  ·  United Kingdom (52)  ·  Germany (49)  ·  Italy (49)  ·  France (46)  ·  Spain (32)  ·  Canada (28)  ·  Australia (25)  ·  Poland (25)  ·  Austria (17)  ·  Belgium (17)  ·  Netherlands (17)  ·  South Korea (15)  ·  Czechia (12)

Top investigators

Lei Zhang, MD (15)  ·  Xiao-Hui Zhang, MD (10)  ·  Xiaohui Zhang, MD (8)  ·  Ruben A. Mesa, MD (4)  ·  Xiaohui Zhang (4)  ·  Alessandro Rambaldi, MD (3)  ·  Cynthia E Dunbar, M.D. (3)  ·  David Gomez-Almaguer, MD (3)  ·  James B Bussel, M.D. (3)  ·  Lei Zhang, M.D. (3)

Results publications

PMID 33783815, PMID 23738544, PMID 24802773, PMID 19846889, PMID 29958797, PMID 34724566, PMID 19005182, PMID 22067384, PMID 23470153, PMID 24802775, PMID 27658437, PMID 29419434, PMID 29674506, PMID 30992268, PMID 32499241, PMID 35030255, PMID 10758304, PMID 11468154, PMID 12353309, PMID 12506176, PMID 15254053, PMID 15389904, PMID 17170128, PMID 17825602, PMID 18046028, PMID 18156492, PMID 18195173, PMID 18463354, PMID 19096013, PMID 19144680, PMID 19208097, PMID 19231632, PMID 19446902, PMID 19731307, PMID 19841031, PMID 20058208, PMID 20110050, PMID 20576011, PMID 20651074, PMID 20841509, PMID 20843246, PMID 20844233, PMID 2110385, PMID 21106014, PMID 21266777, PMID 21636861, PMID 21833452, PMID 21877169, PMID 22223819, PMID 22475545

NIH funding

2018 (7), 2023 (6), 2014 (4), P30CA015083 (4), 2019 (3), P01CA108671 (3), P30CA015704 (3), 2025 (2), P01CA015396 (2), P01CA018029 (2), P30CA006973 (2), P30CA016672 (2), 2004 (1), 2008 (1), 2016 (1)